Similar results were obtained by Alvarez in a double-blind, randomized, placebo-controlled trial in which 46 subjects with early CKD (stages 2–3) were given cholecalciferol (50,000 IU/week for 12 weeks followed by 50,000 IU/every other week for 40 weeks) with a significant reduction in PTH values from baseline (baseline 89.1 ± 49.3 to 70.1 ± 24.8 pg/mL; p = 0.01) [56]. This evidence concerns the gene PTH and chronic kidney disease.